[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence trial evaluating the investigational formulation dapagliflozin tablets (10 mg) versus the reference formulation dapagliflozin tablets (Andatang®/FORXIGA®, 10 mg) in healthy adult trial participants in fasting condition.
主要目的:研究空腹状态下单次口服受试制剂达格列净片(规格:10 mg(按C21H25ClO6计),山东威智百科药业有限公司生产)与参比制剂达格列净片(安达唐®/FORXIGA®,规格:10 mg(按C21H25ClO6计),AstraZeneca Pharmaceuticals LP生产)在健康成年试验参与者体内的药代动力学,评价空腹状态下口服两种制剂的生物等效性。
次要目的:评估受试制剂达格列净片(规格:10 mg(按C21H25ClO6计))和参比制剂达格列净片(安达唐®/FORXIGA®,规格:10 mg(按C21H25ClO6计))在健康成年试验参与者中的安全性。
[Translation] Primary Objective: To investigate the pharmacokinetics of a single oral dose of the test formulation dapagliflozin tablets (10 mg (C21H25ClO6), manufactured by Shandong Weizhi Baike Pharmaceutical Co., Ltd.) and the reference formulation dapagliflozin tablets (Andatang®/FORXIGA®, 10 mg (C21H25ClO6), manufactured by AstraZeneca Pharmaceuticals LP) in healthy adult participants under fasting conditions, and to evaluate the bioequivalence of the two formulations under fasting conditions.
Secondary Objective: To evaluate the safety of the test formulation dapagliflozin tablets (10 mg (C21H25ClO6)) and the reference formulation dapagliflozin tablets (Andatang®/FORXIGA®, 10 mg (C21H25ClO6)) in healthy adult participants.